Shin Nippon Biomedical Laboratories Acquires Satsuma Pharmaceuticals
April 16, 2023
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) has entered into a definitive agreement to acquire all outstanding shares of Satsuma Pharmaceuticals for $0.91 per share in cash plus a non-tradeable contingent value right (CVR) of up to $5.77 per share tied to future monetization of STS101. The transaction gives SNBL ownership of Satsuma's investigational intranasal migraine product STS101 and associated delivery technology, and is supported by Satsuma’s board as maximizing value for stockholders.
- Buyers
- Shin Nippon Biomedical Laboratories, Ltd. (SNBL)
- Targets
- Satsuma Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
GNI Group to Acquire Ayumi Pharmaceutical Holdings from Blackstone for About ¥44.8 Billion
June 8, 2026
Healthcare Services
GNI Group Co., Ltd. agreed to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone for an enterprise value of about ¥44.8 billion. The acquisition will make Ayumi a wholly owned subsidiary of GNI and expand GNI’s commercial presence in Japan, particularly in pain management, rheumatology, and related therapeutic areas.
-
Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline
June 2, 2025
Pharmaceuticals
Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.
-
Otsuka Pharmaceutical Acquires Jnana Therapeutics
August 1, 2024
Biotechnology
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
Shionogi Inc. Acquires Qpex Biopharma, Inc.
June 26, 2023
Pharmaceuticals
Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.
-
Asahi Kasei Medical to Acquire Bionova Scientific
April 14, 2022
Healthcare Services
Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.
-
Shionogi Acquires Tetra Therapeutics
May 26, 2020
Biotechnology
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.